Precision Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
19.6%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$2.49next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| PBGENE-HBV ELIMINATE-B Trial Year-End Update | 31 Dec 2026 |
| PBGENE-DMD FUNCTION-DMD Trial Initial Patient Data | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly125.8MTarget: Fund operations and data milestones through 2028
PBGENE-HBV Patient Enrollment (ELIMINATE-B Trial) Quarterly16.0Target: Complete dosing of Cohorts 3, 4, and 5 to select optimal dose
PBGENE-DMD Clinical Site Activation (FUNCTION-DMD Trial) Quarterly1.0Target: Activate multiple world-class sites and dose first patient
Watch Items
- PBGENE-HBV Clinical Data UpdatesTrigger: Presentation of additional biopsy and viral gene editing data by year-end 2026Action: Evaluate cccDNA elimination permanence and HBsAg decline durability across cohorts
- PBGENE-DMD Initial Patient DataTrigger: Initial clinical data from multiple patients expected by year-end 2026Action: Assess percentage of near full-length dystrophin protein expression from muscle biopsies
- Regulatory Alignment for PBGENE-DMDTrigger: Supportive clinical data from at least 10 DMD patientsAction: Meet with the FDA to align on a regulatory path forward
Research as of 19 Jun 2026